China Remibrutinib manufacturers and suppliers

Remibrutinib

Short Description:

API’s Name	CAS No.	US DMF	Patent Expiry Date (US)	Current Status
Remibrutinib	1787294-07-8	Jun, 2028	Nov.13, 2034	estimated PV Completion - Mar, 2028

[Indication]

Chronic spontaneous urticaria (CSU): For the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.

Send email to us